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CASE REPORT
Angiosarcoma of the scalp presenting in association with
borderline malignant phyllodes tumour of the breast
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Abstract
Phyllodes tumours and angiosarcoma are both rare mesenchymal tumours. There are no reports of their coexistence in the
literature except in families with germline p53 mutations. Here we report a case of an elderly woman who developed an
extensive angiosarcoma of the scalp nearly 4 years after surgical removal of a borderline malignant phyllodes tumour of the
breast. The scalp lesion was initially thought more likely to be a metastasis of her first rare tumour than a second equally rare
primary tumour, but histologically this was not the case. The case and the literature are discussed.
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Case report
An 81-year-old woman, who had previously been
well, presented with a left breast mass. It had
increased in size over several months but mammog-
raphy suggested that it was benign. A 16 15 
8.5-cm phyllodes tumour was excised (Fig. 1). It
showed variable cellularity. There was focal degen-
eration and calcification. No heterologous elements
were recognised. While there was little cytological
pleomorphism, mitoses were readily found (up to
44mm
 2) and the neoplasm extended to the resec-
tion margin. The tumour was regarded as being of
borderline type with a small risk of recurrence or
metastasis. Subsequent studies showed that many of
the stromal cell nuclei, particularly in the more
cellular areas, showed moderate to strong immuno-
staining for p53 protein. Interestingly, similar immu-
noreactivity was present in the epithelial cells.
Four years later, she presented with a non-healing
scalp laceration, with a history of having hit her head
2 months previously. However, the laceration was
found to lie within an extensive bleeding nodular
lesion, which extended over her scalp and onto her
face (Fig. 2). A scalp haematoma was evacuated but
as the lesion continued to bleed; debridement and
skin grafting were performed by the plastic surgeons.
The graft took well, but bleeding continued around
the edges despite her having stopped anticoagulants
(for atrial fibrillation). A biopsy of the lesion
showed cutaneous angiosarcoma (Fig. 3). Its cells
strongly immunostained for CD31 and CD34.
Many of their nuclei showed moderate to strong
immunoreactivity for p53 protein, as did some of the
basal and parabasal keratinocytes of the epidermis
and hair follicles. A CT scan showed no evidence of
bony infiltration. She continued to deteriorate, with
bleeding and disease progression, including bilateral
cervical lymphadenopathy. Palliative radiotherapy
to the scalp reduced the bleeding and discharge
but she became anaemic, developed hyperkalaemia
and died several months after presentation with the
scalp lesion. Post mortem examination was not
undertaken.
Discussion
Phyllodes tumours are rare, constituting less than 1%
of breast neoplasms.
1 Such tumours contain both
stromal and epithelial components, of which the
stromal elements are usually monoclonal and con-
sidered neoplastic.
2 Phyllodes tumours form a
spectrum from benign (35–65%), through borderline
(low-grade malignancy; 11–40%), to frankly malig-
nant (18–35%) variants based on infiltrative margins,
mitotic activity, stromal overgrowth and cellular
atypia.
3–6 Considerable variation exists in the pro-
portions of these subtypes in published series,
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logical interpretation.
5,6 Whilst tumour behaviour
is often unpredictable, those tumours with more
aggressive-looking histological appearances (i.e.,
borderline or frankly malignant) tend to recur locally
and to metastasise.
1,7 Local recurrence is also
associated with adequacy of surgical resection.
8
Local excision with adequate surgical margins is
considered the standard treatment and routine
axillary lymph node dissection is unnecessary
3 as
lymph nodes are rarely involved. Adjuvant radio-
therapy and chemotherapy are not usually necessary.
However, postoperative radiotherapy is usually
recommended for malignant tumours, treating as
for a sarcoma. Metastasising potential has been
associated with repeated local recurrence, increased
mitoses and stromal overgrowth. The most common
site for metastasis is the lungs, with sites such as
bone, brain, pleura, soft tissue and skin occurring
less frequently.
3,5,9,10
There are several theoretical explanations for the
development of the two neoplasms in this case,
including: metastasis of heterologous elements in the
phyllodes tumour; or development of two indepen-
dent primary neoplasms as a result of inherited
genetic abnormality; or acquired constitutional
abnormality; or coincidence.
Metastatic spread to the scalp was considered
likely clinically in this patient in view of her very
large tumour, its focally positive surgical margins,
relatively high mitotic rate and stromal overgrowth.
However, histopathological examination did not
Fig. 1. The borderline phyllodes tumour of the breast. (A) H&E-stained section; (B) p53-immunostained section showing strong
nuclear staining of the stromal cells.
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primary cutaneous angiosarcoma. Thorough exam-
ination of the breast tumour showed no evidence of
heterologous elements. Angiosarcomatous foci can
be seen in malignant phyllodes tumours, but were
not present in this case. There are also no reports in
the literature of phyllodes tumour metastases under-
going angiosarcomatous change, although heterolo-
gous stromal elements (bone, fat, cartilage) in the
primary tumour can rarely become more prominent
in metastases.
1,5,10
Apart from young adults with germline p53
mutations, it is extremely unusual to see the
development of two rare primary mesenchymal
tumours in the same patient.
11,12 We are not aware
of any reports of an association between phyllodes
tumour and angiosarcoma outside of such cases.
Malignant phyllodes tumours of the breast have been
shown to be very strongly associated with germline
p53 mutations. However, it is unlikely that our
patient had a germline p53 mutation in view of her
Fig. 3. The cutaneous angiosarcoma. (A) CD31-immunostained section; (B) p53-immunostained section showing strong
nuclear staining.
Fig. 2. Extensive cutaneous angiosarcoma extending over the
scalp with central laceration.
Angiosarcoma and phyllodes tumour 175advanced age at the time of diagnosis of both tumours
and in the absence of previous history of malignancy.
However, no analysis of her p53 genotype has been
made, so this possibility, although remote, cannot be
completely excluded. The immunostaining for p53
protein seen in the epithelial component of the
phyllodes tumour and in keratinocytes is tantalising,
but its significance is uncertain. It is possible that,
with increasing age, other constitutional changes
(such as immunological) took place, predisposing to
the development of these two rare neoplasms.
However, perhaps the most likely explanation is
that there was no direct link between them.
The diagnosis of angiosarcoma of the scalp
dramatically altered her prognosis. These scalp
tumours tend to be highly aggressive, particularly
when they are as extensive as in this case, often
metastasising to adjacent lymph nodes. Both surgery
and radiotherapy have low rates of local control
because of the diffusely infiltrative nature of the
condition and its potential for rapid multifocal and
metastatic spread.
13,14 The best results for both are
seen with small-volume, localised disease. Liposomal
anthracyclines can cause tumour regression, but this
elderly patient was too frail for this to be considered.
Whilst, in general, metastasis is more common
than the development of a second rare primary
neoplasm, this case report illustrates the fact that
there are exceptions to the rule and emphasises the
importance of undertaking a biopsy of suspected
secondary lesions.
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